Lululemon faucets former Amazon exec as new CEO of its at-home gymnasium Mirror

Michael Aragon was previously the chief content officer of Twitch, Amazon’s live streaming business.

Source: Lululemon

Lululemon said Thursday it called earlier Amazon Managing Director Michael Aragon as Chief Executive Officer of his home gym, Mirror.

Aragon will also oversee Lululemon’s broader digital fitness endeavors, the retailer said in a press releasewho reports directly to the CEO of Lululemon, Calvin McDonald. The changes will take effect on January 17th.

Lululemon bought Mirror for $ 500 million in 2020. In September, then CEO Brynn Putnam resigned from their role. She founded the company in 2016.

Aragon was previously the chief content officer of Twitch, Amazon’s live streaming business. He also held positions at Sony groupto expand the PlayStation network.

In this new role, Aragon will face an increasingly competitive market for connected fitness equipment. Among the rivals are Peloton, Tonal, Hydrow and many others. The category exploded with interest as gyms temporarily closed and consumers looked for ways to exercise at home during the pandemic.

In December, Lululemon lowers its forecast for Mirror sales in fiscal year 2021 between $ 125 million and $ 130 million. Previously, the company had expected sales of $ 250 million to $ 275 million for the device, which will be wall-mounted and allow users to take cardio and other exercise classes.

Separately, Lululemon will oppose a. defend legal action filled in by Nike on Wednesday, which Mirror accused of infringing some of Nike’s patents.

Lululemon responded to the lawsuit by stating that Nike’s patents are “too broad and invalid. We believe in our position and look forward to defending it in court.”

Lululemon shares were unchanged in after-hours trading, closing the day up 1.7% at $ 368.77.

Individuals ought to quickly be capable to get free at-home Covid assessments

Jaruek chair | iStock | Getty Images

Who can get the free trials?

The White House says the 150 million Americans Individuals with private health insurance are eligible for full reimbursement after purchasing a home Covid test. This includes people who are insured with their employer as well as those who bought a plan on the Affordable Care Act marketplace, Dawson said.

The new rules do not apply to Medicaid and Medicare policyholders, although this may change, and Medicare policyholders with private insurance may be covered.

Short-term plans or health-care sharing plans usually don’t have to cover your tests, said Sabrina Corlette, Co-director of the Center on Health Insurance Reforms at the McCourt School of Public Policy at Georgetown University.

Covid tests at home are also possible a refundable expense for flexible savings accounts and health savings accounts.

Can I get any test?

Experts said we will have to wait for further instructions from the government to know what is covered, but they expect most of the home tests available in pharmacies to be included in the policy.

How do I make sure that my insurer reimburses me?

You probably still have some work to do to get the money back, Dawson said.

Many people may not even be familiar with their provider’s refund policy. (You can start learning about this by reaching out to your plan.)

It will be important that you keep your receipt, said Caitlin Donovan, a spokeswoman for the Patient Advocate Foundation

“Your normal receipt should be fine – I even printed out receipts from Amazon – and then you’d have to send it in,” Donovan said, adding that insurers usually have a reimbursement form that you want to fill out.

“Insurers usually have a physical mailing address,” she said. “They may also have an option for electronic submission, which means you can upload them to their website or email them.”

To send a simpler receipt, Donovan recommends asking the cashier to call the tests separately from further purchases.

Corlette hopes government guidelines in January will require insurers to reimburse people for bills within a certain timeframe.

“It can take some companies a long time to cut these checks,” Corlette said.

What if i don’t have insurance?

If you don’t have insurance or are covered by Medicaid and Medicare, the White House doubles the number of free tests it distributes in community centers from 25 million to 50 million.

You should be able to find one of these centers on your state or local health agency website, Corlette said.

When should I do a home test?

VioletaStoimenova | E + | Getty Images

Dawson mentioned some of the most common circumstances people might want to test for the virus: They have come into contact with someone who has been diagnosed with Covid, they show symptoms of the virus, or they are expected to participate in a risk event, such as a large family gathering or a meeting with an immunocompromised person.

Can I use a home test on the go?

Most take-away tests bought at your local Walgreens, for example, don’t provide results for you to use before a flight or cruise. However, there is at least one home test that the CDC has approved for travel purposes. according to the travel site The Points Guy.

5 Ideas for Saving on At-Dwelling Leisure This 12 months

TipRanks

2 “Strong Buy” stocks that trade at strong discounts

Regardless of whether the markets are moving up or down, every investor loves a bargain. It’s exciting to find a valuable stock at a low price – and then see it appreciate in the medium to long term. The key for investors is finding options where the risk-reward combination works towards long-term benefit. So how are investors supposed to distinguish between the names who are ready to get back on their feet and those who are supposed to stay in the dumps? That’s what the pros on Wall Street are for. Using TipRanks’ database, we identified two seedy stocks that analysts believe are preparing for a rebound. Despite the heavy losses over the past 52 weeks, the two tickers have received enough street praise to earn a consensus rating of “Strong Buy”. Theravance Biopharma (TBPH) We’re starting Theravance, a biopharmaceutical company focused on developing organ-specific drugs. The current pipeline includes drug candidates for the treatment of inflammatory lung and bowel diseases and neuro-orthostatic hypotension. The research programs range from phase 1 to phase 3 studies. Theravance already has YUPELRI on the market as a COPD treatment. YUPELRI accounts for the lion’s share of Theravance’s sales, reaching $ 18.3 million in the third quarter. This was an increase of 47% over the previous year and a 124% increase in YUPELRI sales. Of greater interest to investors, Trelegy Ellipta, GlaxoSmithKline’s new once-daily inhalation medication developed as a maintenance therapy for asthma and which was approved by the FDA in September 2020, has a broad potential audience as asthma affects more than 350 million people worldwide. Theravance owns licensing rights to Trelegy with an estimated income of 5.5% to 8.5% of total sales. Trelegy was originally approved in the United States as the first triple once-daily single inhaler therapy for the treatment of COPD. Like many biopharmaceuticals, Theravance has a high overhead and the approved drugs are at the beginning of their profitable lives. This keeps net income and sales low, at least for the short term, and results in a discounted share price – TBPH has declined 32% in the past 52 weeks. Analyst Geoff Porges, who covers the stock for Leerink, remains bullish on Theravance, largely due to the combination of its robust pipeline and approved treatments for lung disease. “Theravance’s respiratory drugs are the top short-term valuation drivers … We are still forecasting ~ $ 2.4 billion in WW triple sales at peak times (2027E). In addition to TBPH’s commercial / partnership assets, the company is also developing an improved JAK inhibitor (JAKi) in collaboration with JNJ (OP) for inflammatory bowel disease (IBD) and a norepinephrine and serotonin reuptake inhibitor (NSRI) TD-9855 (ampreloxetine) for neurogenic orthostatic hypotension (nOH). Each of these drugs uses the novel delivery of unique compounds against proven mechanisms of action and, due to their broader therapeutic window, could offer superior safety and / or treatment effects, ”said Porges. To do this, Porges rates TBPH as outperforming (i.e. buying) and gives it a price target of $ 35, which is an impressive uptrend of 104% for a year. (To see Porges’ track record, click here.) There are 5 total reviews and all are for sale so the consensus on the strong buy is unanimous. TBPH shares are priced at $ 16.95, and their average target price of $ 33.60 indicates an upward movement of 97% from that level. (See TBPH stock analysis on TipRanks) NiSource, Inc. (NI) NiSource is a utility holding company with subsidiaries in the natural gas and electricity sectors. NiSource supplies power and gas to over 4 million customers in Indiana, Kentucky, Maryland, Massachusetts, Ohio, Pennsylvania, and Virginia. The majority of NiSource’s customers, approximately 88%, are in the gas sector. The company’s electrical operations only serve customers in Indiana. The company had third-quarter revenues of $ 902 million, up from $ 962 in the previous quarter and $ 931 in the year-ago quarter. Overall, however, sales have adjusted to the company’s historical pattern: the second and third quarters are relatively low, while return on sales rises with the cold weather in the fourth quarter and highs in the first quarter. This is typical of utility companies in North America. Despite lower year-over-year sales, NiSource was confident enough to maintain its dividend payment and keep it steady at 21 cents per common share through 2020. This corresponds to an annual return of 84 cents and a return of 3.8%. Not only was the company confident of paying returns to shareholders, but also confident of investing heavily in renewable energy sources. The company has an investment plan for fiscal year 20 of more than $ 1.7 billion and expects fiscal year 21 to reach $ 1.3 billion. These expenses are used to finance “green” energy projects. NI is currently trading at $ 21.67, a notable distance from its 52-week low. However, one analyst believes that this lower stock price is an attractive entry point for investors today. Argus analyst Gary Hovis rates NI a Buy along with a price target of $ 32. This number implies an upward movement of 48% from the current level. (To see Hovis’ track record, click here.) “NI stocks appear to be valued cheaply at 18.1 times our EPS estimate for 2021, which is below the average multiple of 21.6 for comparable power companies. and gas supplier, “said Hovis. “NiSource could also become a buyout target as larger utilities and private equity firms have bought smaller utilities because of their stable earnings growth and above-average dividend yields.” Overall, Wall Street sees a clear path for NiSource – a fact that emerges from Strong Buy’s unanimous consensus rating based on three recent buy-side ratings. The shares sell for $ 21.68, and the average target price of $ 28.75 indicates an upside of ~ 32% over the year-ago period. (See NI Stock Analysis on TipRanks.) To find great ideas for trading rundown stocks at attractive valuations, visit TipRanks’ Best Stocks to Buy, ‘a newly launched tool that brings together all of TipRanks’ stock insights. Disclaimer: The opinions expressed in this article are solely those of the analysts presented. The content is intended to be used for informational purposes only. It is very important that you do your own analysis before making any investment.